MORTIMER IAN

PRESIDENT & CEO

MORTIMER IAN has filed 6 SEC Form 4 filings (26 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Mar 13, 2026.

On the most recent filing, MORTIMER IAN is listed as PRESIDENT & CEO at Xenon Pharmaceuticals Inc. Inside the rolling window, MORTIMER IAN reported no open-market purchases and 8 open-market sales totaling $21.3M in XENE. The largest disclosed transaction in the window is a sale of 270,000 XENE shares on Mar 9, 2026, worth $16.3M.

Companies traded

Other insiders at XENE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$21.3M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
XENESale$404KMar 13SEC ↗
XENESale$16.3MMar 11SEC ↗
XENESale$677KMar 11SEC ↗
XENESale$1.8MJan 2SEC ↗
XENESale$647KDec 9SEC ↗
XENESale$495KDec 9SEC ↗
XENESale$4KDec 3SEC ↗
XENESale$1.0MOct 1SEC ↗
Showing 1–8 of 8
1 / 1

Frequently asked questions

How many SEC Form 4 filings has MORTIMER IAN made?

MORTIMER IAN has filed 6 SEC Form 4 filings (26 transaction rows) across 1 company since 2025.

Which companies does MORTIMER IAN trade?

MORTIMER IAN has filed SEC Form 4 disclosures for 1 company, including XENE.

When was MORTIMER IAN's most recent SEC Form 4 filing?

MORTIMER IAN's most recent SEC Form 4 filing on Tracefour is dated Mar 13, 2026.

What is MORTIMER IAN's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, MORTIMER IAN is listed as PRESIDENT & CEO.

What is MORTIMER IAN's total buy and sell value in the current window?

Inside the rolling retention window, MORTIMER IAN bought $0 and sold $21.3M based on SEC Form 4 filings.

What was MORTIMER IAN's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 270,000 XENE shares on 2026-03-09, worth $16.3M, per SEC Form 4 filings.